(Reuters) – Endo International Plc (O:), Johnson & Johnson (N:) and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP’s bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter.
Five drugmakers battling the cases – Endo, J&J, Teva Pharmaceutical (NYSE:) Industries Ltd (TA:) , Allergan Plc (N:) and Mallinckrodt Plc (N:) – are looking to enact a global settlement of the litigation that would be implemented through Purdue’s Chapter 11 case, the WSJ reported citing a person familiar with the matter.
The mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability, according to the report. (https://on.wsj.com/2nVksYH)
OxyContin maker Purdue filed for bankruptcy protection in September, succumbing to pressure from more than 2,600 lawsuits alleging the company helped fuel the deadly U.S. opioid epidemic.
Purdue, Mallinckrodt, Endo, J&J, Teva and Allergan were not immediately available to Reuters’ requests for comment.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.